GHRH(1-29) analogue

Sermorelin

GHRH · GH / IGF-1

Sermorelin is the 1-29 fragment of human GHRH and stimulates pituitary GH release. It was historically used for diagnostics and growth-hormone deficiency, but modern anti-ageing and body-composition claims lack a comparable evidence base.

2Overview
1× / dayReference frequency
DataHuman endocrine physiology
Research status

Historical diagnostic medicine; current wellness claims not established

Velora Sermorelin vial
SERMORELIN10 MG
01 · Overview

What is Sermorelin?

Sermorelin is the 1-29 fragment of human GHRH and stimulates pituitary GH release. It was historically used for diagnostics and growth-hormone deficiency, but modern anti-ageing and body-composition claims lack a comparable evidence base.

Research route, formulation and population determine what a result actually means.

01

GHRH

Activates the GHRH receptor and stimulates pituitary growth-hormone release.

02

GH / IGF-1

An increase in pituitary GH can raise downstream IGF-1 production; this is not direct IGF-1-receptor activation.

02 · Research

What do the studies show?

Human endocrine physiology. Educational information. Not diagnosis, treatment or use advice.

03 · DATA

Peptide and product specifications

Checked identity data for this research compound or blend.

SermorelinPeptide and product specifications
Molecular formula
C₁₄₉H₂₄₇N₄₄O₄₃S (FDA: geschatte formule)
Molecular weight
3357.91 Da (berekende gemiddelde massa)
CAS number
86168-78-7
Amino-acid sequence / components
Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH₂
Amino-acid count
29
Purity
Batch-specific - confirm identity and purity with the Velora COA
Reference diluent
Formulation- and batch-specific; there is no universal diluent for every research compound
Unreconstituted-material storage
Follow the accompanying COA, product label and validated stability data

These are compound references, not a batch certificate. Purity and identity of a specific Velora batch must be confirmed by its accompanying COA and laboratory report.

FDA Global Substance Registration System ↗
04 · Calculator

Reconstitution and U-100 conversion

This module only converts concentration and volume. Inputs are not recommendations or individual dosing advice.

Calculator

Once daily in educational protocols

1
2
3
4
Draw to
0 units
0.00 mL
Sermorelin vial
SERMORELIN
10 MG
Concentration-
Per unit-
Complete amounts-
Calculated duration-
LAB · RECONSTITUTION

How to reconstitute Sermorelin for laboratory research

A visual workflow for controlled laboratory reconstitution. Always follow the product label, COA and a validated protocol.

Five visual laboratory reconstitution steps: clean, measure diluent, add slowly, swirl gently and store according to protocol.
1

Clean

Disinfect the rubber closures of both vials and allow them to dry.

2

Measure diluent

Withdraw only the diluent validated for the specific compound.

3

Add slowly

Let the liquid run slowly down the inside wall of the vial.

4

Swirl gently

Do not shake; rotate gently until the material has dissolved.

5

Store per protocol

Follow the product label, COA and validated stability data.

Important checks before and after reconstitution

Check the product

First confirm that the product is a lyophilised vial. Prefilled pens and ready-to-use solutions do not require reconstitution. Check the label, COA and specified diluent.

Use clean, sterile technique

Wash your hands, clean the work surface and use new sterile equipment for every procedure. Clean both rubber closures with separate alcohol swabs and let them dry completely.

Concentration, not total amount

The volume of liquid added changes the concentration in mg per mL, but not the total amount of research compound in the vial. Use the calculator to check this in advance.

Inspect and label

Check for unexpected discoloration, cloudiness or visible particles. Record the compound, concentration and reconstitution date. Storage time and temperature are product-specific; a fixed 28-day rule does not apply to every compound.

General reconstitution volumes listed by the source

General examples, not a product-specific protocol. The chosen volume determines concentration; always check the label, COA and calculator.

Vial strengthCommonly listed volume
2 mg1–2 mL
5 mg2–3 mL
6 mg2–3 mL
10 mg2–4 mL
15 mg3–5 mL
20 mg4–8 mL

Practical background source: Free Medical Journals - Complete Step-by-Step Guide to Peptide Reconstitution, accessed July 2026. This is a secondary educational source; the product label, COA and validated stability data remain authoritative.

05 · Safety and limitations

Safety and limitations

Research route, formulation and population determine what a result actually means.

What is known

  • Visible research claims use primary or official sources.
  • The calculator is arithmetic and does not turn a study amount into medical advice.
  • A registered medicine and a research vial are not automatically equivalent.

What remains uncertain

  • Many products lack long-term safety data and independent replication.
  • Animal and cell findings do not predict a safe human dose.
  • Stability depends on formulation, pH, sterility, light, temperature and packaging.
Status: Historical diagnostic medicine; current wellness claims not established. Educational information. Not diagnosis, treatment or use advice.
06 · FAQ

Frequently asked questions

Sermorelin is the 1-29 fragment of human GHRH and stimulates pituitary GH release. It was historically used for diagnostics and growth-hormone deficiency, but modern anti-ageing and body-composition claims lack a comparable evidence base.
Sermorelin is used in stimulation tests to assess GH reserve; response varies substantially with age and visceral fat. Diagnostic GH stimulation does not prove lasting clinical benefit in healthy adults.
No. It performs arithmetic conversions only. Medical decisions belong with a licensed healthcare professional.
The curve follows the agreed storage model and is not a laboratory result.
2–8 °C. Protect from light and repeated freeze-thaw cycles.
07 · Sources

Primary research sources

Educational information. Not diagnosis, treatment or use advice.

Central adiposity and GH response to GHRH-arginine testing Journal of Clinical Endocrinology & Metabolism, 2008. Link
Growth hormone-releasing hormone testing and physiology Endocrine literature search, 2026. Link